Home » Stocks » ACRX

AcelRx Pharmaceuticals, Inc. (ACRX)

Stock Price: $1.03 USD -0.04 (-3.74%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $1.04 +0.01 (0.97%) May 13, 5:09 PM
Market Cap 123.63M
Revenue (ttm) 5.42M
Net Income (ttm) -40.38M
Shares Out 85.26M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $1.03
Previous Close $1.07
Change ($) -0.04
Change (%) -3.74%
Day's Open 1.07
Day's Range 1.02 - 1.09
Day's Volume 1,852,221
52-Week Range 1.01 - 2.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced a poster presentation at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting reviewing the results of a study on the intraoperative...

7 hours ago - Benzinga

HAYWARD, Calif., May 13, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx),  a specialty pharmaceutical company focused on the development and commercialization of innovative th...

9 hours ago - PRNewsWire

HAYWARD, Calif., May 10, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after ...

3 days ago - PRNewsWire

HAYWARD, Calif., May 6, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative ther...

1 week ago - PRNewsWire

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced an investigator-initiated study to assess the perioperative use of Dsuvia (sufentanil sublingual tablet) for same-day surgical procedures in patie...

1 month ago - Benzinga

REDWOOD CITY, Calif., April 8, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovati...

1 month ago - PRNewsWire

REDWOOD CITY, Calif., March 31, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therap...

1 month ago - PRNewsWire

REDWOOD CITY, Calif., March 25, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therap...

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such inve...

1 month ago - Newsfile Corp

NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX).  Such investors are advi...

1 month ago - PRNewsWire

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 16.67% and -1.60%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 44.44% year over year to ($0.10), which were ...

1 month ago - Benzinga

REDWOOD CITY, Calif., March 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovat...

1 month ago - PRNewsWire

NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX).  Such investors are advi...

2 months ago - PRNewsWire

AcelRx Pharmaceuticals and Sundial Growers could both be poised for a major growth spurt.

Other stocks mentioned: SNDL
2 months ago - The Motley Fool

REDWOOD CITY, Calif., March 8, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter financial results...

2 months ago - PRNewsWire

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

The company announced the pricing of a public stock offering.

3 months ago - The Motley Fool

REDWOOD CITY, Calif., Jan. 19, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovativ...

3 months ago - PRNewsWire

Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Dec. 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapi...

5 months ago - PRNewsWire

REDWOOD CITY, Calif., Dec. 9, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...

5 months ago - PRNewsWire

REDWOOD CITY, Calif., Dec. 4, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...

5 months ago - PRNewsWire

Acelrx shares plummeted after the company released third quarter earnings. However, numbers were significantly up compared to any prior period.

6 months ago - Seeking Alpha

REDWOOD CITY, Calif., Nov. 6, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...

6 months ago - PRNewsWire

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -42.86% and -77.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the st...

6 months ago - Zacks Investment Research

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7 months ago - Zacks Investment Research

AcelRx (ACRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Sept. 29, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovat...

7 months ago - PRNewsWire

REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

7 months ago - PRNewsWire

REDWOOD CITY, Calif., Aug. 19, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

8 months ago - PRNewsWire

ACRX Shareholders had a lot to digest during the past three months, including capital raise, cancelled and new marketing agreements, and the exit from the Tetraphase bidding war.

9 months ago - Seeking Alpha

AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

9 months ago - Zacks Investment Research

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 42.86% and -25.03%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

REDWOOD CITY, Calif., Aug. 10, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

9 months ago - PRNewsWire

REDWOOD CITY, Calif., Aug. 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.

9 months ago - PRNewsWire

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other stocks mentioned: BDSI, BNFT, CLRB, LNT
9 months ago - Zacks Investment Research

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

REDWOOD CITY, Calif., June 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative...

11 months ago - PRNewsWire

REDWOOD CITY, Calif., June 1, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapie...

11 months ago - PRNewsWire

AcelRx Pharmaceuticals: Finally Light At The End Of The Tunnel

11 months ago - Seeking Alpha

AcelRx Pharmaceuticals: Lean Back And Watch The Rocket Launch

11 months ago - Seeking Alpha

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -33.33% and -85.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

AcelRx Pharmaceuticals (ACRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

About ACRX

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 14, 2011
CEO
Vincent Angotti
Employees
54
Stock Exchange
NASDAQ
Ticker Symbol
ACRX
Full Company Profile

Financial Performance

In 2020, ACRX's revenue was $5.42 million, an increase of 136.61% compared to the previous year's $2.29 million. Losses were -$40.38 million, -24.16% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ACRX stock is "Buy." The 12-month stock price forecast is 6.67, which is an increase of 547.57% from the latest price.

Price Target
$6.67
(547.57% upside)
Analyst Consensus: Buy